{"id":348034,"date":"2025-08-25T13:51:10","date_gmt":"2025-08-25T13:51:10","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-sage-therapeutics\/"},"modified":"2025-08-25T13:51:10","modified_gmt":"2025-08-25T13:51:10","slug":"how-to-buy-sage-therapeutics","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/","title":{"rendered":"How to buy Sage Therapeutics, Inc. (SAGE) shares &#8211; Investment in Sage Therapeutics, Inc. (SAGE) stock"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-348034","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Sage Therapeutics, Inc. (SAGE) Shares - Investment in Sage Therapeutics, Inc. (SAGE) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Sage Therapeutics, Inc. (SAGE) Shares - Investment in Sage Therapeutics, Inc. (SAGE) Stock"},"description":"Learn how to invest in Sage Therapeutics (SAGE) stock, understand current price trends, acquisition impacts, and make informed decisions about this biopharmaceutical company's shares.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to invest in Sage Therapeutics (SAGE) stock, understand current price trends, acquisition impacts, and make informed decisions about this biopharmaceutical company's shares."},"intro":"Thinking about investing in a company that's making waves in mental health treatment? Sage Therapeutics (SAGE) offers a fascinating story of innovation, acquisition, and market transformation. With groundbreaking treatments for postpartum depression and a recent major acquisition, this stock presents unique opportunities for savvy investors looking to understand the biopharmaceutical sector.","intro_source":{"label":"Intro","type":"text","formatted_value":"Thinking about investing in a company that's making waves in mental health treatment? Sage Therapeutics (SAGE) offers a fascinating story of innovation, acquisition, and market transformation. With groundbreaking treatments for postpartum depression and a recent major acquisition, this stock presents unique opportunities for savvy investors looking to understand the biopharmaceutical sector."},"body_html":"<h2>\ud83d\udcc8 Sage Therapeutics Stock: Current Price and Market Position<\/h2> <p>As of August 25, 2025, Sage Therapeutics (SAGE) is trading at <strong>$8.68<\/strong> per share. This price comes at a pivotal moment in the company's history, following its recent acquisition by Supernus Pharmaceuticals.<\/p> <p><strong>Mark your calendar: November 4, 2025<\/strong> is absolutely critical for SAGE investors. That's when the company will release its next earnings report under Supernus ownership. Historically, earnings reports have been major catalysts for biotech stocks like Sage.<\/p> <h3>How Major News Events Have Moved SAGE Stock<\/h3> <table> <thead> <tr><th>Date<\/th><th>Event<\/th><th>Pre-News Price<\/th><th>Post-News Change<\/th><\/tr> <\/thead> <tbody> <tr><td>July 30, 2025<\/td><td>Q2 Earnings Release<\/td><td>$8.95<\/td><td>-3.0% (acquisition uncertainty)<\/td><\/tr> <tr><td>June 16, 2025<\/td><td>Supernus Acquisition Announcement<\/td><td>$7.20<\/td><td>+20.6% (deal premium excitement)<\/td><\/tr> <tr><td>January 2025<\/td><td>Biogen Offer Rejection<\/td><td>$5.80<\/td><td>+24.1% (higher valuation hopes)<\/td><\/tr> <tr><td>August 2023<\/td><td>Zurzuvae FDA Approval<\/td><td>$15.40<\/td><td>+42.8% (initial approval euphoria)<\/td><\/tr> <tr><td>Early 2024<\/td><td>MDD Application Rejection<\/td><td>$12.80<\/td><td>-58.2% (major setback)<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend Insight<\/strong>: Positive regulatory news typically drives significant price spikes (+20-40%), while setbacks cause dramatic declines. The acquisition news provided a healthy premium, but uncertainty around integration has created recent volatility.<\/p>  [cta_green text=\"Start trading\"]<h2>\ud83d\udcca 6-Month Price Journey: Rollercoaster Recovery<\/h2> <p>Sage Therapeutics shares have experienced a remarkable transformation over the past six months, climbing <strong>approximately 50%<\/strong> from February to August 2025:<\/p> <ul> <li><strong>February 2025<\/strong>: $5.80 (post-MDD rejection lows, Biogen offer rejection)<\/li> <li><strong>April 2025<\/strong>: $6.90 (acquisition speculation building)<\/li> <li><strong>June 2025<\/strong>: $8.65 (Supernus deal announcement excitement)<\/li> <li><strong>July 2025<\/strong>: $9.10 (deal completion anticipation)<\/li> <li><strong>August 2025<\/strong>: $8.68 (post-acquisition reality check)<\/li> <\/ul> <p>This recovery story demonstrates how biotech stocks can rebound dramatically from regulatory setbacks when strategic opportunities emerge.<\/p>  <h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2> <p>Based on current acquisition terms and market dynamics, here's what to expect:<\/p> <ul> <li><strong>2025 Year-End<\/strong>: $8.50-9.00 (acquisition cash payout level) \u2192 <strong>HOLD<\/strong><\/li> <li><strong>2026<\/strong>: $3.50-12.00 range (contingent value rights dependent on Zurzuvae performance)<\/li> <li><strong>2028<\/strong>: $5.00-15.00 (long-term integration success with Supernus)<\/li> <li><strong>2030<\/strong>: $8.00-20.00 (full pipeline integration and market expansion)<\/li> <\/ul> <p><strong>Verdict<\/strong>: The acquisition creates a binary outcome - either the CVRs pay off substantially or investors receive minimal additional value. This makes SAGE a <strong>speculative hold<\/strong> rather than a clear buy or sell.<\/p>  <h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2> <h3>Risks to Consider<\/h3> <ul> <li><strong>Acquisition integration risk<\/strong>: Merging two pharmaceutical companies often creates operational challenges<\/li> <li><strong>Zurzuvae commercial uncertainty<\/strong>: The CVR payments depend on sales milestones that may not be achieved<\/li> <li><strong>Regulatory dependency<\/strong>: Future revenue depends on successful drug commercialization and potential new approvals<\/li> <li><strong>Market volatility<\/strong>: Biotech stocks typically experience higher price swings than established companies<\/li> <\/ul> <h3>Green Lights for 2025-2026<\/h3> <ul> <li><strong>Immediate cash payout<\/strong>: $8.50 per share provides downside protection<\/li> <li><strong>Growth potential<\/strong>: CVRs offer up to $3.50 additional per share if commercial targets are met<\/li> <li><strong>Strategic fit<\/strong>: Supernus's neuropsychiatry focus aligns perfectly with Sage's pipeline<\/li> <li><strong>Cost synergies<\/strong>: Projected $200 million annual savings from the acquisition<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2> <ol> <li><strong>Understand the acquisition structure<\/strong>: You're essentially buying two components - the guaranteed $8.50 cash and speculative CVRs<\/li> <li><strong>Size appropriately<\/strong>: This is a speculative position - allocate no more than 2-5% of your portfolio<\/li> <li><strong>Monitor milestones<\/strong>: Track Zurzuvae prescription data and quarterly reports from Supernus<\/li> <li><strong>Humorous take<\/strong>: \"Trading SAGE now is like ordering mystery box takeout - you know you're getting the rice ($8.50), but the main course could be filet mignon or leftover tofu ($3.50 CVR)\"<\/li> <\/ol>  <h2>\u2705 How to Buy Sage Therapeutics, Inc. (SAGE) Shares - Step by Step<\/h2> <table> <thead> <tr><th>Step<\/th><th>Action<\/th><th>Why It Matters<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Choose a trading platform<\/td><td>Ensure it offers OTC\/pink sheet trading since SAGE will delist from Nasdaq<\/td><\/tr> <tr><td>2<\/td><td>Complete account funding<\/td><td>Start with a small amount given the speculative nature<\/td><\/tr> <tr><td>3<\/td><td>Search for \"SAGE\"<\/td><td>Use the ticker symbol, not just the company name<\/td><\/tr> <tr><td>4<\/td><td>Select order type<\/td><td>Use limit orders to control your entry price precisely<\/td><\/tr> <tr><td>5<\/td><td>Review acquisition terms<\/td><td>Understand you're buying rights to both cash and potential CVR payments<\/td><\/tr> <tr><td>6<\/td><td>Confirm purchase<\/td><td>Double-check fees and settlement details<\/td><\/tr> <tr><td>7<\/td><td>Set price alerts<\/td><td>Monitor for important milestone announcements<\/td><\/tr> <tr><td>8<\/td><td>Track performance<\/td><td>Follow Supernus earnings reports for updates<\/td><\/tr> <tr><td>9<\/td><td>Consider tax implications<\/td><td>Acquisition may create unique tax treatment<\/td><\/tr> <tr><td>10<\/td><td>Review regularly<\/td><td>Reassess your position after each earnings report<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2> <p>For those looking to dip their toes into speculative biotech investing, Pocket Option offers several advantages:<\/p> <ul> <li><strong>Minimum deposit of just $5<\/strong> - perfect for testing strategies with SAGE without significant risk<\/li> <li><strong>Rapid verification<\/strong> - get started quickly with minimal documentation requirements<\/li> <li><strong>Multiple withdrawal options<\/strong> - flexibility when you want to realize gains or adjust positions<\/li> <li><strong>Educational resources<\/strong> - learn about acquisition arbitrage and special situation investing<\/li> <\/ul>  <h2>\ud83c\udf0d Sage Therapeutics in 2025: Acquisition Transformation<\/h2> <p>Sage Therapeutics now operates as part of Supernus Pharmaceuticals following the $795 million acquisition finalized in August 2025. The company developed the only two FDA-approved treatments for postpartum depression - Zulresso (IV formulation) and Zurzuvae (oral medication).<\/p> <p><strong>Current Focus<\/strong>: Integration into Supernus's neuropsychiatry portfolio, maximizing Zurzuvae commercialization, and leveraging Sage's CNS discovery platform for future development.<\/p> <p><strong>2025 Interesting Fact<\/strong>: During the acquisition process, Sage's research team discovered that their office plants had been named by employees after various neurotransmitters - \"Serotonin Sally\" and \"Dopamine Dave\" became minor celebrities in biotech social media circles!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Sage Therapeutics Stock: Current Price and Market Position<\/h2>\n<p>As of August 25, 2025, Sage Therapeutics (SAGE) is trading at <strong>$8.68<\/strong> per share. This price comes at a pivotal moment in the company&#8217;s history, following its recent acquisition by Supernus Pharmaceuticals.<\/p>\n<p><strong>Mark your calendar: November 4, 2025<\/strong> is absolutely critical for SAGE investors. That&#8217;s when the company will release its next earnings report under Supernus ownership. Historically, earnings reports have been major catalysts for biotech stocks like Sage.<\/p>\n<h3>How Major News Events Have Moved SAGE Stock<\/h3>\n<table>\n<thead>\n<tr>\n<th>Date<\/th>\n<th>Event<\/th>\n<th>Pre-News Price<\/th>\n<th>Post-News Change<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>July 30, 2025<\/td>\n<td>Q2 Earnings Release<\/td>\n<td>$8.95<\/td>\n<td>-3.0% (acquisition uncertainty)<\/td>\n<\/tr>\n<tr>\n<td>June 16, 2025<\/td>\n<td>Supernus Acquisition Announcement<\/td>\n<td>$7.20<\/td>\n<td>+20.6% (deal premium excitement)<\/td>\n<\/tr>\n<tr>\n<td>January 2025<\/td>\n<td>Biogen Offer Rejection<\/td>\n<td>$5.80<\/td>\n<td>+24.1% (higher valuation hopes)<\/td>\n<\/tr>\n<tr>\n<td>August 2023<\/td>\n<td>Zurzuvae FDA Approval<\/td>\n<td>$15.40<\/td>\n<td>+42.8% (initial approval euphoria)<\/td>\n<\/tr>\n<tr>\n<td>Early 2024<\/td>\n<td>MDD Application Rejection<\/td>\n<td>$12.80<\/td>\n<td>-58.2% (major setback)<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend Insight<\/strong>: Positive regulatory news typically drives significant price spikes (+20-40%), while setbacks cause dramatic declines. The acquisition news provided a healthy premium, but uncertainty around integration has created recent volatility.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/en\/register\/\" class=\"po-cta-green\">Start trading\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6-Month Price Journey: Rollercoaster Recovery<\/h2>\n<p>Sage Therapeutics shares have experienced a remarkable transformation over the past six months, climbing <strong>approximately 50%<\/strong> from February to August 2025:<\/p>\n<ul>\n<li><strong>February 2025<\/strong>: $5.80 (post-MDD rejection lows, Biogen offer rejection)<\/li>\n<li><strong>April 2025<\/strong>: $6.90 (acquisition speculation building)<\/li>\n<li><strong>June 2025<\/strong>: $8.65 (Supernus deal announcement excitement)<\/li>\n<li><strong>July 2025<\/strong>: $9.10 (deal completion anticipation)<\/li>\n<li><strong>August 2025<\/strong>: $8.68 (post-acquisition reality check)<\/li>\n<\/ul>\n<p>This recovery story demonstrates how biotech stocks can rebound dramatically from regulatory setbacks when strategic opportunities emerge.<\/p>\n<h2>\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>\n<p>Based on current acquisition terms and market dynamics, here&#8217;s what to expect:<\/p>\n<ul>\n<li><strong>2025 Year-End<\/strong>: $8.50-9.00 (acquisition cash payout level) \u2192 <strong>HOLD<\/strong><\/li>\n<li><strong>2026<\/strong>: $3.50-12.00 range (contingent value rights dependent on Zurzuvae performance)<\/li>\n<li><strong>2028<\/strong>: $5.00-15.00 (long-term integration success with Supernus)<\/li>\n<li><strong>2030<\/strong>: $8.00-20.00 (full pipeline integration and market expansion)<\/li>\n<\/ul>\n<p><strong>Verdict<\/strong>: The acquisition creates a binary outcome &#8211; either the CVRs pay off substantially or investors receive minimal additional value. This makes SAGE a <strong>speculative hold<\/strong> rather than a clear buy or sell.<\/p>\n<h2>\u26a0\ufe0f Key Risks vs. Positive Signals<\/h2>\n<h3>Risks to Consider<\/h3>\n<ul>\n<li><strong>Acquisition integration risk<\/strong>: Merging two pharmaceutical companies often creates operational challenges<\/li>\n<li><strong>Zurzuvae commercial uncertainty<\/strong>: The CVR payments depend on sales milestones that may not be achieved<\/li>\n<li><strong>Regulatory dependency<\/strong>: Future revenue depends on successful drug commercialization and potential new approvals<\/li>\n<li><strong>Market volatility<\/strong>: Biotech stocks typically experience higher price swings than established companies<\/li>\n<\/ul>\n<h3>Green Lights for 2025-2026<\/h3>\n<ul>\n<li><strong>Immediate cash payout<\/strong>: $8.50 per share provides downside protection<\/li>\n<li><strong>Growth potential<\/strong>: CVRs offer up to $3.50 additional per share if commercial targets are met<\/li>\n<li><strong>Strategic fit<\/strong>: Supernus&#8217;s neuropsychiatry focus aligns perfectly with Sage&#8217;s pipeline<\/li>\n<li><strong>Cost synergies<\/strong>: Projected $200 million annual savings from the acquisition<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f What Should a Beginner Trader Do Today?<\/h2>\n<ol>\n<li><strong>Understand the acquisition structure<\/strong>: You&#8217;re essentially buying two components &#8211; the guaranteed $8.50 cash and speculative CVRs<\/li>\n<li><strong>Size appropriately<\/strong>: This is a speculative position &#8211; allocate no more than 2-5% of your portfolio<\/li>\n<li><strong>Monitor milestones<\/strong>: Track Zurzuvae prescription data and quarterly reports from Supernus<\/li>\n<li><strong>Humorous take<\/strong>: &#8220;Trading SAGE now is like ordering mystery box takeout &#8211; you know you&#8217;re getting the rice ($8.50), but the main course could be filet mignon or leftover tofu ($3.50 CVR)&#8221;<\/li>\n<\/ol>\n<h2>\u2705 How to Buy Sage Therapeutics, Inc. (SAGE) Shares &#8211; Step by Step<\/h2>\n<table>\n<thead>\n<tr>\n<th>Step<\/th>\n<th>Action<\/th>\n<th>Why It Matters<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Choose a trading platform<\/td>\n<td>Ensure it offers OTC\/pink sheet trading since SAGE will delist from Nasdaq<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Complete account funding<\/td>\n<td>Start with a small amount given the speculative nature<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Search for &#8220;SAGE&#8221;<\/td>\n<td>Use the ticker symbol, not just the company name<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Select order type<\/td>\n<td>Use limit orders to control your entry price precisely<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Review acquisition terms<\/td>\n<td>Understand you&#8217;re buying rights to both cash and potential CVR payments<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Confirm purchase<\/td>\n<td>Double-check fees and settlement details<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Set price alerts<\/td>\n<td>Monitor for important milestone announcements<\/td>\n<\/tr>\n<tr>\n<td>8<\/td>\n<td>Track performance<\/td>\n<td>Follow Supernus earnings reports for updates<\/td>\n<\/tr>\n<tr>\n<td>9<\/td>\n<td>Consider tax implications<\/td>\n<td>Acquisition may create unique tax treatment<\/td>\n<\/tr>\n<tr>\n<td>10<\/td>\n<td>Review regularly<\/td>\n<td>Reassess your position after each earnings report<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Why Pocket Option Fits New Investors<\/h2>\n<p>For those looking to dip their toes into speculative biotech investing, Pocket Option offers several advantages:<\/p>\n<ul>\n<li><strong>Minimum deposit of just $5<\/strong> &#8211; perfect for testing strategies with SAGE without significant risk<\/li>\n<li><strong>Rapid verification<\/strong> &#8211; get started quickly with minimal documentation requirements<\/li>\n<li><strong>Multiple withdrawal options<\/strong> &#8211; flexibility when you want to realize gains or adjust positions<\/li>\n<li><strong>Educational resources<\/strong> &#8211; learn about acquisition arbitrage and special situation investing<\/li>\n<\/ul>\n<h2>\ud83c\udf0d Sage Therapeutics in 2025: Acquisition Transformation<\/h2>\n<p>Sage Therapeutics now operates as part of Supernus Pharmaceuticals following the $795 million acquisition finalized in August 2025. The company developed the only two FDA-approved treatments for postpartum depression &#8211; Zulresso (IV formulation) and Zurzuvae (oral medication).<\/p>\n<p><strong>Current Focus<\/strong>: Integration into Supernus&#8217;s neuropsychiatry portfolio, maximizing Zurzuvae commercialization, and leveraging Sage&#8217;s CNS discovery platform for future development.<\/p>\n<p><strong>2025 Interesting Fact<\/strong>: During the acquisition process, Sage&#8217;s research team discovered that their office plants had been named by employees after various neurotransmitters &#8211; &#8220;Serotonin Sally&#8221; and &#8220;Dopamine Dave&#8221; became minor celebrities in biotech social media circles!<\/p>\n"},"faq":[{"question":"Can I still buy Sage Therapeutics stock after the acquisition?","answer":"Yes, but it now trades over-the-counter rather than on Nasdaq, and you're essentially buying rights to the $8.50 cash payment plus potential CVR value."},{"question":"What are the contingent value rights (CVRs)?","answer":"CVRs are additional payments you may receive if Zurzuvae achieves specific commercial sales milestones, worth up to $3.50 per share."},{"question":"How long will the acquisition process take?","answer":"The deal closed July 31, 2025, but CVR payments may occur over several years as sales targets are met."},{"question":"Should I buy SAGE for long-term investment?","answer":"This is now a special situation investment rather than a traditional long-term hold, suitable only for investors comfortable with acquisition arbitrage strategies."},{"question":"How does this affect existing shareholders?","answer":"Existing shareholders will receive $8.50 per share in cash and one CVR per share, with the total potential value being $12.00 per share if all milestones are achieved."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Can I still buy Sage Therapeutics stock after the acquisition?","answer":"Yes, but it now trades over-the-counter rather than on Nasdaq, and you're essentially buying rights to the $8.50 cash payment plus potential CVR value."},{"question":"What are the contingent value rights (CVRs)?","answer":"CVRs are additional payments you may receive if Zurzuvae achieves specific commercial sales milestones, worth up to $3.50 per share."},{"question":"How long will the acquisition process take?","answer":"The deal closed July 31, 2025, but CVR payments may occur over several years as sales targets are met."},{"question":"Should I buy SAGE for long-term investment?","answer":"This is now a special situation investment rather than a traditional long-term hold, suitable only for investors comfortable with acquisition arbitrage strategies."},{"question":"How does this affect existing shareholders?","answer":"Existing shareholders will receive $8.50 per share in cash and one CVR per share, with the total potential value being $12.00 per share if all milestones are achieved."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>How to buy Sage Therapeutics, Inc. (SAGE) shares - Investment in Sage Therapeutics, Inc. (SAGE) stock<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"How to buy Sage Therapeutics, Inc. (SAGE) shares - Investment in Sage Therapeutics, Inc. (SAGE) stock\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T13:51:10+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"How to buy Sage Therapeutics, Inc. (SAGE) shares &#8211; Investment in Sage Therapeutics, Inc. (SAGE) stock\",\"datePublished\":\"2025-08-25T13:51:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/\"},\"wordCount\":17,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/\",\"name\":\"How to buy Sage Therapeutics, Inc. (SAGE) shares - Investment in Sage Therapeutics, Inc. (SAGE) stock\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"datePublished\":\"2025-08-25T13:51:10+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"How to buy Sage Therapeutics, Inc. (SAGE) shares &#8211; Investment in Sage Therapeutics, Inc. (SAGE) stock\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/en\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"How to buy Sage Therapeutics, Inc. (SAGE) shares - Investment in Sage Therapeutics, Inc. (SAGE) stock","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"How to buy Sage Therapeutics, Inc. (SAGE) shares - Investment in Sage Therapeutics, Inc. (SAGE) stock","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T13:51:10+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"How to buy Sage Therapeutics, Inc. (SAGE) shares &#8211; Investment in Sage Therapeutics, Inc. (SAGE) stock","datePublished":"2025-08-25T13:51:10+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/"},"wordCount":17,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/","url":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/","name":"How to buy Sage Therapeutics, Inc. (SAGE) shares - Investment in Sage Therapeutics, Inc. (SAGE) stock","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","datePublished":"2025-08-25T13:51:10+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-sage-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/en\/"},{"@type":"ListItem","position":2,"name":"How to buy Sage Therapeutics, Inc. (SAGE) shares &#8211; Investment in Sage Therapeutics, Inc. (SAGE) stock"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/en\/#website","url":"https:\/\/pocketoption.com\/blog\/en\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/en\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/en\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":348113,"slug":"how-to-buy-sage-therapeutics","post_title":"Comment acheter des actions de Sage Therapeutics, Inc. (SAGE) - Investissement dans les actions de Sage Therapeutics, Inc. (SAGE)","href":"https:\/\/pocketoption.com\/blog\/fr\/news-events\/signal\/how-to-buy-sage-therapeutics\/"},"it_IT":{"locale":"it_IT","id":348116,"slug":"how-to-buy-sage-therapeutics","post_title":"Come acquistare azioni di Sage Therapeutics, Inc. (SAGE) - Investire in azioni di Sage Therapeutics, Inc. (SAGE)","href":"https:\/\/pocketoption.com\/blog\/it\/news-events\/signal\/how-to-buy-sage-therapeutics\/"},"pl_PL":{"locale":"pl_PL","id":348111,"slug":"how-to-buy-sage-therapeutics","post_title":"Jak kupi\u0107 akcje Sage Therapeutics, Inc. (SAGE) - Inwestycja w akcje Sage Therapeutics, Inc. (SAGE)","href":"https:\/\/pocketoption.com\/blog\/pl\/news-events\/signal\/how-to-buy-sage-therapeutics\/"},"es_ES":{"locale":"es_ES","id":348112,"slug":"how-to-buy-sage-therapeutics","post_title":"C\u00f3mo comprar acciones de Sage Therapeutics, Inc. (SAGE) - Inversi\u00f3n en acciones de Sage Therapeutics, Inc. (SAGE)","href":"https:\/\/pocketoption.com\/blog\/es\/news-events\/signal\/how-to-buy-sage-therapeutics\/"},"th_TH":{"locale":"th_TH","id":348114,"slug":"how-to-buy-sage-therapeutics","post_title":"\u0e27\u0e34\u0e18\u0e35\u0e0b\u0e37\u0e49\u0e2d\u0e2b\u0e38\u0e49\u0e19 Sage Therapeutics, Inc. (SAGE) - \u0e01\u0e32\u0e23\u0e25\u0e07\u0e17\u0e38\u0e19\u0e43\u0e19\u0e2b\u0e38\u0e49\u0e19 Sage Therapeutics, Inc. (SAGE)","href":"https:\/\/pocketoption.com\/blog\/th\/news-events\/signal\/how-to-buy-sage-therapeutics\/"},"tr_TR":{"locale":"tr_TR","id":348115,"slug":"how-to-buy-sage-therapeutics","post_title":"Sage Therapeutics, Inc. (SAGE) Hisseleri Nas\u0131l Al\u0131n\u0131r - Sage Therapeutics, Inc. (SAGE) Hisse Senedi Yat\u0131r\u0131m\u0131","href":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-sage-therapeutics\/"},"vt_VT":{"locale":"vt_VT","id":348110,"slug":"how-to-buy-sage-therapeutics","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Sage Therapeutics, Inc. (SAGE) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Sage Therapeutics, Inc. (SAGE)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-sage-therapeutics\/"},"pt_AA":{"locale":"pt_AA","id":348109,"slug":"how-to-buy-sage-therapeutics","post_title":"Como comprar a\u00e7\u00f5es da Sage Therapeutics, Inc. (SAGE) - Investimento em a\u00e7\u00f5es da Sage Therapeutics, Inc. (SAGE)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-sage-therapeutics\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/348034","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/comments?post=348034"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/posts\/348034\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media\/334108"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/media?parent=348034"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/categories?post=348034"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/en\/wp-json\/wp\/v2\/tags?post=348034"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}